Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to <scp>TOPAZ</scp> ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting

Federica Lo Prinzi, Gian Paolo Spinelli, Masafumi Ikeda et al.|International Journal of Cancer|2026

Cited by 0